Latest Reimbursement News

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Magellan Asset Management is shifting its flagship MGOC ETF to a new systematic equity strategy managed by Vinva Investment Management, slashing fees and eliminating performance charges.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Nuix has appointed John Ruthven as its permanent CEO and Managing Director, ending a global search and signalling leadership continuity following his interim role since November 2025.

Sierra Nevada Gold (ASX: SNX) has swiftly mobilised three drill rigs to commence a 5,000m Phase 1 program at its As Safra copper-gold project in Saudi Arabia, following exploration licence approval by Royal Decree. The campaign targets a district-scale mineralised system with results expected by late May.

Strategic Energy Resources (ASX:SER) has locked in a $6 million joint venture with Sumitomo for its Bulimba Gold Project, secured $400,000 in government grants for drilling, and completed capital consolidation, positioning itself for a busy exploration season in Queensland.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.